Clinical Trial Update: A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors [Phase 1]

View source ↗

Summary

A Phase I study of pazopanib as a single agent for children with refractory solid tumors has been withdrawn from the trial program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Neuroblastoma
• Osteosarcoma
• Sarcoma
• Wilms Tumor

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Sarcoma, Neuroblastoma | Phase 1 | Status: WITHDRAWN